Antibody responses to HPV16 virus-like particles in women with cervical intraepithelial neoplasia infected with a variant HPV16 [4]

Lancet

Volumn 349, Issue 9058, 1997, Pages 1069-1070

  Ellis, J R M ^b   Etherington, I ^b   Galloway, D ^b   Luesley, D ^b   Young, L S ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY;

ANTIBODY RESPONSE; FEMALE; HUMAN; LETTER; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

EID: 0030991406     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)62292-1     Document Type: Article

References (5)

1. Zur Hausen H. Human papillomavirus in the pathogenesis of anogenital cancer. Virology 1991; 184: 9-13.
2. Ellis JRM, Keating PJ, Baird J, et al.The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nat Med 1995; 1: 464-70.
3. Carter JJ, Koutsky LA, Wipf GC, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996; 174: 927-36.
4. Kirnbauer RF, Taub J, Greenstone H, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993; 67: 6929-36.
5. Cheng G, Icenogle JP, Kirnbauer R, et al. Divergent human papillomavirus type 16 variants are serologically cross-reactive. J Infect Dis 1995; 172: 1584-87.